A. Nagler et al., ENGRAFTMENT FOLLOWING MITOXANTRONE (MITO) BASED CONDITIONING FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (ALLO-BMT), Leukemia research, 22(3), 1998, pp. 209-213
Mitoxantrone (Mito) is presently used in an increasing number of malig
nancies including leukemias, breast carcinomas and solid tumors. With
it has come increased incidence of post remission cytopenias and delay
ed engraftment following autologous bone marrow transplantation (ABMT)
. We evaluated engraftment in 18 patients who underwent allogeneic BMT
(allo-BMT) following a preparative regimen that included high dose Mi
te (60 mg m(2)). Sixteen patients with malignant disease (AML 10, ALL
3, CML 2, MDS 1) and two with non-malignant disease (SCID 1, osteopetr
osis 1) underwent non-T cell depleted allo-BMT. Fourteen patients with
malignancies were transplanted at an advanced stage of disease while
only two patients were standard risk patients. Of the 18 patients, 12
were females and six males, with a median age of 30.5 (0.3-48) years.
Nine patients, (breast cancer 3, malignant lymphoma 4 and AML 2), who
underwent ABMT following preparative regimens with comparable doses of
Mite, served as controls. Engraftment following allo-BMT was normal a
nd not statistically different from engraftment following ABMT. Five p
atients, who underwent allo-BMT, developed >grade II acute graft versu
s host disease (GVHD) and two developed chronic GVHD. After a median f
ollow up of 28 (6-42) months, five patients are alive tone with diseas
e). In summary, engraftment following high dose Mite and allo-BMT is n
ot statistically different from engraftment following ABMT. Controlled
studies with a larger group of standard risk patients are needed to e
lucidate the role of Mite in conditioning regimens pre-BMT. (C) 1998 E
lsevier Science Ltd. All rights reserved.